A clinical validation study of Trevyent

Trial Profile

A clinical validation study of Trevyent

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2017 According to a SteadyMed Therapeutics media release, the company has submitted a Type A Meeting Request and Briefing Document to the U.S. Food and Drug Administration (FDA) in response to a Refusal to File letter relating to its New Drug Application (NDA) for Trevyent.
    • 31 Aug 2017 According to a SteadyMed Therapeutics media release, the company has announced receipt of a Refusal to File letter from the U.S. Food and Drug Administration (FDA) relating to its New Drug Application (NDA) for Trevyent for the treatment of Pulmonary Arterial Hypertension (PAH).
    • 12 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top